Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

658 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S. Di Lorenzo G, et al. Among authors: longo n. J Clin Oncol. 2009 Sep 20;27(27):4469-74. doi: 10.1200/JCO.2009.22.6480. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652053 Clinical Trial.
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S. Di Lorenzo G, et al. Among authors: longo n. Eur Urol. 2007 Oct;52(4):1020-7. doi: 10.1016/j.eururo.2007.02.060. Epub 2007 Mar 7. Eur Urol. 2007. PMID: 17360103 Clinical Trial.
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S. Di Lorenzo G, et al. Among authors: longo n. Anticancer Drugs. 2009 Apr;20(4):277-80. doi: 10.1097/CAD.0b013e328329a293. Anticancer Drugs. 2009. PMID: 19262371 Clinical Trial.
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V. Di Lorenzo G, et al. Among authors: longo n. Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24. Eur Urol. 2010. PMID: 20884115
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Di Lorenzo G, et al. Among authors: longo n. Eur Urol. 2011 Dec;60(6):1280-4. doi: 10.1016/j.eururo.2011.08.028. Epub 2011 Aug 22. Eur Urol. 2011. PMID: 21871710 Clinical Trial.
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Buonerba C, Ferro M, Dolce P, Crocetto F, Verde A, Lucarelli G, Scafuri L, Facchini S, Vaia A, Marinelli A, Terracciano D, Montella L, Longo N, Imbimbo C, Mirone V, Di Lorenzo G, De Placido S, Sonpavde G. Buonerba C, et al. Among authors: longo n. Crit Rev Oncol Hematol. 2020 Jul;151:102992. doi: 10.1016/j.critrevonc.2020.102992. Epub 2020 May 23. Crit Rev Oncol Hematol. 2020. PMID: 32474391
658 results